SCLXW
Scilex Holding Company
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.11
−5.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 31.6M | 30.3M | 56.6M | 46.7M | 38.0M |
| Cost of Revenue | 18.5M | 15.2M | 16.7M | 15.7M | 10.8M |
| Gross Profit | 13.1M | 15.0M | 39.9M | 31.1M | 27.2M |
| Operating Expenses | |||||
| R&D Expense | 18.6M | 20.7M | 9.6M | 12.7M | 9.1M |
| SG&A Expense | 277.0M | 266.6M | 119.0M | 119.6M | 64.9M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.1M | — | (5.4M) | 4.1M | 3.9M |
| Total Operating Expenses | 298.7M | 287.3M | 123.3M | 136.5M | 77.9M |
| Cost and Expenses | 317.2M | 302.6M | 140.0M | 152.2M | 88.7M |
| Operating Income (EBIT) | (285.6M) | (272.3M) | (83.4M) | (105.4M) | (50.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 16.2M | 11.5M | 2.0M | 1.1M | 9.6M |
| Net Interest Income | (16.2M) | (11.5M) | (2.0M) | (1.1M) | (9.6M) |
| Other Non-Op Income/Expense | (179.0M) | (101.7M) | 10.6M | (8.9M) | 27.3M |
| Non-Operating Income (excl Interest) | 83.3M | 90.3M | (12.6M) | 7.8M | (36.9M) |
| EBT (Pre-Tax Income) | (464.5M) | (374.0M) | (72.8M) | (114.3M) | (23.4M) |
| Income Tax Expense | 12.0K | 26.0K | (1.0K) | 13.0K | 4.0K |
| Bottom Line | |||||
| Net Income | (447.1M) | (358.7M) | (72.8M) | (114.3M) | (23.4M) |
| Earnings from Cont. Ops | (464.6M) | (374.1M) | (72.8M) | (114.3M) | (23.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (448.3M) | (402.5M) | (72.8M) | (167.0M) | (23.4M) |
| Per Share | |||||
| Basic EPS | ($64.88) | ($36.48) | ($19.43) | ($44.85) | ($6.09) |
| Diluted EPS | ($64.88) | ($36.48) | ($19.43) | ($44.85) | ($6.09) |
| Revenue Per Share | $4.59 | $2.74 | $8.14 | $12.56 | $9.92 |
| Shares | |||||
| Basic Shares Outstanding | 6.9M | 11.0M | 7.0M | 3.7M | 3.8M |
| Diluted Shares Outstanding | 6.9M | 11.0M | 7.0M | 3.7M | 3.8M |
| Profitability Metrics | |||||
| EBITDA | (360.6M) | (357.9M) | (66.8M) | (109.1M) | (9.3M) |
| D&A | 8.3M | 4.6M | 4.0M | 4.1M | 4.5M |
| EBIT | (368.9M) | (362.6M) | (70.8M) | (113.3M) | (13.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026